Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.35 |
| ▸ | KDM6B | O15054 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449998 | 0.81 | KDM4E (0.37) | KDM4ETSHR | |
| SCHEMBL15740568 | 0.77 | KAT2B (0.37) | — | |
| SCHEMBL15749026 | 0.75 | TDP1 (0.36) | TSHRHCAR3 | |
| SCHEMBL12456743 | 0.74 | UHRF1 (0.34) | KDM4EMAP4K4 | |
| SCHEMBL24270763 | 0.74 | ALDH1A1 (0.44) | KDM4EHCAR3 | |
| SCHEMBL29492781 | 0.74 | ALDH1A1 (0.44) | KDM4EHCAR3 | |
| SCHEMBL31599717 | 0.74 | MAPT (0.48) | ESR1MEN1KMT2A | |
| SCHEMBL20529705 | 0.73 | IL1B (0.31) | KDM4EMEN1KMT2A | |
| SCHEMBL15749318 | 0.71 | KDM4E (0.51) | KDM4E | |
| SCHEMBL15740528 | 0.71 | IDH1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111251-A1 | COMPOUNDS THAT INHIBIT POLO-LIKE KINASE 4 | EXELIXIS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |